{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:29:13Z","timestamp":1785176953103,"version":"3.55.0"},"reference-count":37,"publisher":"JLE","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.nephro.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T06:15:58Z","timestamp":1496297758000},"page":"S83-S87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Traitement de la glom\u00e9rulon\u00e9phrite extramembraneuse"],"prefix":"10.1684","volume":"13","author":[{"given":"Karine","family":"Dahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"issue":"2","key":"10.1016\/j.nephro.2017.02.002_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ndt\/gfp355","article-title":"An overview on frequency of renal biopsy diagnosis in Brazil: clinical and pathological patterns based on 9617\u00a0native kidney biopsies","volume":"25","author":"Polito","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.nephro.2017.02.002_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2215\/CJN.00710805","article-title":"Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study","volume":"1","author":"Swaminathan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.nephro.2017.02.002_bib0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ki.1988.56","article-title":"Idiopathic membranous nephropathy: the natural history of untreated patients","volume":"33","author":"Donadio","year":"1988","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.nephro.2017.02.002_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nephro.2017.02.002_bib0025","first-page":"73","article-title":"Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome","volume":"2","author":"Zucchelli","year":"1987","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.02.002_bib0030","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspension","volume":"100","author":"Heymann","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.nephro.2017.02.002_bib0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.157.2.667","article-title":"Immunocytochemical localization of the Heymann nephritis antigen (gp330) in glomerular epithelial cells of normal Lewis rats","volume":"157","author":"Kerjaschki","year":"1983","journal-title":"J Exp Med"},{"key":"10.1016\/j.nephro.2017.02.002_bib0040","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.002_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2\u00a0receptor as target antigen in idiopathic MN","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.002_bib0050","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1\u00a0domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.002_bib0055","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1\u00a0and PLA2R1\u00a0alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.002_bib0060","first-page":"186","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"Suppl. 2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.nephro.2017.02.002_bib0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1056\/NEJM198901263200403","article-title":"A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy","volume":"320","author":"Cattran","year":"1989","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nephro.2017.02.002_bib0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nephro.2017.02.002_bib0075","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2017.02.002_bib0080","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.nephro.2017.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","article-title":"Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate","volume":"19","author":"du Buf-Vereijken","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.nephro.2017.02.002_bib0090","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporne in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.nephro.2017.02.002_bib0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.nephro.2017.02.002_bib0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.nephro.2017.02.002_bib0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.nephro.2017.02.002_bib0110","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1046\/j.1523-1755.1999.00675.x","article-title":"Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy","volume":"56","author":"Berg","year":"1999","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.nephro.2017.02.002_bib0115","first-page":"CD004293","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.nephro.2017.02.002_bib0120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2\u00a0receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2017.02.002_bib0125","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2\u00a0receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.nephro.2017.02.002_bib0130","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.nephro.2017.02.002_bib0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.nephro.2017.02.002_bib0140","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.nephro.2017.02.002_bib0145","doi-asserted-by":"crossref","first-page":"e110681","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin\u2013angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.nephro.2017.02.002_bib0150","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfv228","article-title":"Spontaneous remission of proteinuria is a frequent event in phospholipase A2\u00a0receptor antibody negative patients with membranous nephropathy","volume":"30","author":"Hoxha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.nephro.2017.02.002_bib0155","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2215\/CJN.03850414","article-title":"M-type phospholipase A2\u00a0receptor autoantibodies and renal function in patients with primary membranous nephropathy","volume":"9","author":"Hoxha","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.nephro.2017.02.002_bib0160","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1681\/ASN.2015080953","article-title":"Combined assessment of phospholipase A2\u00a0receptor autoantibodies and glomerular deposits in membranous nephropathy","volume":"27","author":"Qin","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.nephro.2017.02.002_bib0165","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2\u00a0receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2017.02.002_bib0170","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"9337","key":"10.1016\/j.nephro.2017.02.002_bib0175","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.nephro.2017.02.002_bib0180","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2017.02.002_bib0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.02.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:42:01Z","timestamp":1741192921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517300433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":37,"alternative-id":["S1769725517300433"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.02.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de la glom\u00e9rulon\u00e9phrite extramembraneuse","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}